Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Apr;72(4):608-610.
doi: 10.1136/gutjnl-2022-327782. Epub 2022 Jun 30.

Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?

Satoru Morita  1 , Dan G Duda  2
Affiliations
Comment

Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?

Satoru Morita et al. Gut. 2023 Apr.
No abstract available

Keywords: CHOLANGIOCARCINOMA; IMMUNOLOGY.

PubMed Disclaimer

Conflict of interest statement

Competing interests: DGD received consultant fees from Innocoll and preclinical research grants from Bayer, Exelixis, Surface Oncology and BMS.

Figures

Figure. 1
Figure. 1. Proposed strategy for treatment selection using tumor microenvironmentbased classification of intrahepatic cholangiocarcinoma.
TME, tumor microenvironment; IFN, interferon; Tregs, regulatory T cells; BAP1, BRCA1–associated protein 1; IDH1/2, Isocitrate dehydrogenase 1/2; FGFR2, fibroblast growth factor receptor; CNV, chromosomal number variation; KRAS, Kirsten Rat Sarcoma; TGFβ, Transforming growth factor beta; AKT, protein kinase B; mTOR, mammalian target of rapamycin; YAP, yes-associated protein; MYC; myelocytomatosis, PD-1; Programmed death 1; PD-L1; Programmed death-ligand 1, CDK inh; cyclin dependent kinase inhibitor. Illustration made using BioRender and reproduced with permission from BMJ.
See this image and copyright information in PMC

Comment on

  • Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
    Martin-Serrano MA, Kepecs B, Torres-Martin M, Bramel ER, Haber PK, Merritt E, Rialdi A, Param NJ, Maeda M, Lindblad KE, Carter JK, Barcena-Varela M, Mazzaferro V, Schwartz M, Affo S, Schwabe RF, Villanueva A, Guccione E, Friedman SL, Lujambio A, Tocheva A, Llovet JM, Thung SN, Tsankov AM, Sia D. Martin-Serrano MA, et al. Gut. 2023 Apr;72(4):736-748. doi: 10.1136/gutjnl-2021-326514. Epub 2022 May 18. Gut. 2023. PMID: 35584893 Free PMC article.

References

    1. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020;17:557–88. - PMC - PubMed
    1. Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet 2015;47:1003–10. - PubMed
    1. Ghassan P, Abou-Alfa K, Sahai V, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020;21:671–84. doi: 10.1016/S1470-2045(20)30109-1 - DOI - PMC - PubMed
    1. Ghassan P, Abou-Alfa K, Macarulla T, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020;21:796–807. - PMC - PubMed
    1. Oh D-Y, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. N Engl J Med 2022;ePub on June 1, 2022 as doi: 10.1056/EVIDoa2200015. - DOI - PubMed

Publication types